Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.41 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16463566 | 0.92 | GPR119 (0.44) | DNMT3AALDH1A1GPR119MAPTNPC1 | |
| SCHEMBL17140268 | 0.87 | ALDH1A1 (0.43) | ALDH1A1GPR119MAPTNPC1MAPK1 | |
| SCHEMBL16463771 | 0.86 | EPHX2 (0.44) | ALDH1A1GPR119MAPTNPC1MAPK1 | |
| SCHEMBL17140281 | 0.86 | ALDH1A1 (0.46) | ALDH1A1GPR119MAPTNPC1MAPK1 | |
| SCHEMBL16463385 | 0.85 | ALDH1A1 (0.47) | DNMT3AALDH1A1MAPTNPC1MAPK1 | |
| SCHEMBL16462077 | 0.85 | EPHX2 (0.47) | DNMT3AALDH1A1GPR119MAPTNPC1 | |
| SCHEMBL17140321 | 0.85 | GPR119 (0.43) | DNMT3AALDH1A1GPR119MAPTNPC1 | |
| SCHEMBL16464781 | 0.84 | BCHE (0.45) | ALDH1A1HTTTEAD1 | |
| SCHEMBL5012643 | 0.83 | ALDH1A1 (0.58) | ALDH1A1GPR119MAPTNPC1MAPK1 | |
| SCHEMBL16464176 | 0.82 | POLB (0.58) | ALDH1A1GPR119MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2906216-B1 | INHIBITORS OF DNA GYRASE FOR THE TREATMENT OF BACTERIAL INFECTIONS | KUMAR AJAY (GB) | 2020-06-24 | — | — | EP | disclosed |
| US-9643979-B2 | Inhibitors of DNA gyrase for the treatment of bacterial infections | VITAS PHARMA RESEARCH PRIVATE LIMITED (IN) | 2017-05-09 | — | — | US | disclosed |
| US-20150284408-A1 | INHIBITORS OF DNA GYRASE FOR THE TREATMENT OF BACTERIAL INFECTIONS | KUMAR, AJAY, DR. (GB) | 2015-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284408-A1 | INHIBITORS OF DNA GYRASE FOR THE TREATMENT OF BACTERIAL INFECTIONS | TOP1, TOP2A, DNASE1 | DNMT3A 54/4885ALDH1A1 3693/4885GPR119 4865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.